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Autosomal dominant polycystic kidney disease (ADPKD)
largely results from mutations in the PKD1 gene leading
to hyperproliferation of renal tubular epithelial cells and
consequent cyst formation. Rodent models of PKD suggest
that the multifunctional hormone insulin-like growth factor-1
(IGF-1) could play a pathogenic role in renal cyst formation.
In order to test this possibility, conditionally immortalized
renal epithelial cells were prepared from normal individuals
and from ADPKD patients with known germline mutations in
PKD1. All patient cell lines had a decreased or absence of
polycystin-1 but not polycystin-2. These cells had an
increased sensitivity to IGF-1 and to cyclic AMP, which
required phosphatidylinositol-3 (PI3)-kinase and the
mitogen-activated protein kinase, extracellular
signal-regulated protein kinase (ERK) for enhanced growth.
Inhibition of Ras or Raf abolished the stimulated cell
proliferation. Our results suggest that haploinsufficiency of
polycystin-1 lowers the activation threshold of the Ras/Raf
signalling system leading to growth factor-induced
hyperproliferation. Inhibition of Ras or Raf activity may
be a therapeutic option for decreasing tubular cell
proliferation in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited human renal disease (incidence
one in 1000 live births) and is caused by mutations in two
genes, PKD1 (85%) and PKD2 (15%). ADPKD is an
important cause of end-stage renal failure, accounting for
B10% of patients on renal replacement therapy. Fluid-filled
cysts form in the kidney but cysts also commonly arise in the
liver and pancreas. There is also an increased incidence of
non-cystic extrarenal manifestations in ADPKD such as
cardiac valve abnormalities, diverticular disease, and intra-
cranial aneurysms.1
The ADPKD proteins, polycystin-1 (PC1) and polycystin-
2 (PC2), are believed to function as a complex, activating a
number of key signalling pathways which in turn regulate
diverse cellular functions.2,3 Cystic epithelial cells are
characterized by a complex phenotype which includes
changes in proliferation, apoptosis, fluid secretion, and
matrix turnover. The increase in cell proliferation appears
to be a consistent feature in human PKD tissue and in many
experimental models of PKD.4–6 Of relevance, it may presage
cyst formation and there is evidence that inhibition of
tubular cell proliferation may ameliorate the severity of the
in vivo cystic phenotype in some rodent PKD models.7
Insulin-like growth factor-1 (IGF-1) is a multifunctional
hormone which has pleiotropic effects on cellular proliferation,
apoptosis, hypertophy, senescence, and differentiation. Several
lines of evidence suggested that IGF-1 may play a role in
mediating tubular cell proliferation in the cystic kidney. First,
kidney IGF-1 content in a rodent PKD model, the Han:SPRD
rat, increased in parallel with the severity of cystic disease.
Dietary lowering of kidney IGF-1 concentrations (soy bean
diet) resulted in a parallel reduction in cystic disease severity.8
Second, kidney IGF-1 mRNA is increased by fourfold in the
recessive pcy mouse model which is orthologous to nephro-
nopthisis Type III and characterized by rapidly progressive
cystic disease.9 Third, mice transgenic for human growth
hormone display a range of renal pathological changes which
include pronounced cystic tubular dilatation.10
Identification of early key changes in cell signalling
occurring downstream of PC1 or PC2 inactivation could
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lead to new therapeutic targets in ADPKD. This study
therefore sought to examine the downstream signalling
events induced by IGF-1 stimulation in vitro using several
unique kidney cell lines derived from patients with defined
germline PKD1 mutations. We also examined if this response
was distinct from that mediated by cAMP.
RESULTS
Polycystin expression in ADPKD cell lines
In one patient (OX938), three lines (C6, C7, C8) were
generated from cells isolated from three individual cysts. In
the other patients (OX161, SKI-001), cells derived from
different cysts were pooled and cultured together. The
germline PKD1 mutations for OX938 (exon 16, 7000dup7)
and OX161 (exon 15, E1537X) have been previously
published and are predicted to truncate the protein proximal
to the REJ domain (Figure 1a).11 Significantly, all the ADPKD
cell lines demonstrated a decrease in full-length PC1
expression which ranged from near absence in OX161 to
being less than 50% in the other lines (Figure 1b). Of interest,
we also detected smaller bands in one of the OX938 clones
(C7) and in SKI-001 which appeared to be of different
mobility to a major band detected at B200 kDa in the two
normal lines, UCL93/3 and CL11. The latter could represent
a splice form but it is possible that the other N-terminal
bands could be mutant, short PC1 proteins. The germline
mutation in OX938 might generate a predicted protein of
B300 kDa but the germline mutation in SKI-001 (IVS43-
1G4A) cannot account for the lower band observed in this
line. A somatic mutation (402delG), which is predicted to
truncate the normal PKD1 allele, was also detected in OX161
cystic DNA in addition to the germline mutation (E1537X)
(Figure 1c). This probably accounts for the absence of full-
length PC1 in OX161. Normal levels of PC2 were present in
all cystic cells regardless of the level of PC1 (Figure 1b). We
did not detect PKD2 mutations in any lines (data not
shown).
Cystic cells are more sensitive to IGF-1 than normal cells
We investigated the expression of the LT antigen at different
temperatures in the cystic cell line, SKI-001. As shown in
Figure 2a, cells grew at the permissive temperature (331C) but
not at non-permissive temperatures (37 and 391C). The
destabilization of the temperature-sensitive LT antigen at
371C was further demonstrated by immunofluorescence
staining (Figure 2b). Expression of cell junction markers
such as cadherins was maintained at permissive and non-
permissive temperatures (Figure 2b). Similar results were
obtained with the cystic cell line, OX161 (data not shown).
To investigate if there were any differences in the effect of
IGF-1 on cell proliferation relating to a reduction in PC1, we
initially compared the response of the cystic cell line SKI-001
to that of a normal line, UCL93. In normal cells, IGF-1
behaved as a weak mitogen (B10–15% above control), over a
wide concentration range (0.001–1000 ng/ml) (Figure 2). In
cystic cells however, IGF-1 stimulated cell proliferation in a
dose-dependent manner, as measured using a cell prolifera-
tion assay (Figure 2c) or by cell counts (Figure 2d).
cAMP stimulates cell proliferation in cystic cells but not
in normal cells
ADPKD cystic cells have been reported to show a phenotypic
switch to a cAMP-stimulatory proliferative response. Simi-
larly, we found that the cAMP analogue dibutyryl cAMP
(dbcAMP) induced cell proliferation in cystic but not in
normal cells (Figure 3a). Elevation of cAMP levels using
other agents (forskolin, 3-isobutyl-l-methylxanthine) pro-
duced a similar difference in responsiveness. Of interest, a
combination of IGF-1 and dbcAMP demonstrated an
additive effect (Figure 3a). These findings could be
reproduced in all three cystic lines studied (Figure 3b) and
suggest that IGF-1 and cAMP may be activating different
signalling pathways.
Surface expression of the IGF-1 receptor is similar between
normal and cystic cells
We compared the surface expression of the IGF-1 receptor
between normal and cystic cells by surface biotinylation. As
shown in Figure 3c, no difference in surface receptor
abundance was apparent between the two lines. This indicates
that the increased responsiveness of cystic cells to IGF-1 is
unlikely to be related to differences in receptor number.
IGF-1- and cAMP-induced proliferation in cystic cells is
dependent of phosphatidylinositol (PI3)-kinase and
extracellular signal regulated protein kinase (ERK) activity
IGF-1 and cAMP have been reported to activate several well-
characterized signalling cascades involved in cell proliferation
such as the PI3-kinase/Akt and the ERK kinase/ERK path-
ways. To analyse the involvement of both pathways in the
above response, we utilized specific inhibitors to PI3-kinase
(LY924002) and ERK kinase (PD98059). In initial experi-
ments, both inhibited the individual and combined response
of IGF-1 and dbcAMP in cystic cells in a dose-dependent
manner (data not shown). The effect was reproducible for
both inhibitors in all three cystic lines (Figure 4a). Another
ERK kinase inhibitor, UO126, similarly inhibited cell
proliferation in response to IGF-1 and cAMP in a dose-
dependent manner (data not shown).
The effectiveness of the kinase inhibitors in the treated
cells was analyzed by immunoblotting using phospho-specific
antibodies raised against pAkt and p44/42 ERK (Figure 4b).
As expected, p44/42 ERK and pAkt were undetectable in the
presence of PD98059 and LY924002, respectively, despite
IGF-1 stimulation. In cystic cells, IGF-1 stimulated small
increases in p44/42 (1.4-fold increase over unstimulated) and
a larger increase in pAkt (9.8-fold increase over unstimu-
lated) in three experiments (Figure 4b). Small increases in
p44/42 (1.7-fold) and pAkt (1.2-fold) were observed in
normal cells. Incubation with dbcAMP did not alter either
p44/42 or pAkt despite the inhibitory effects of the kinase
inhibitors (data not shown). These results suggest that
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PI3-kinase and ERK activity may be permissive for the cAMP
proliferative response rather than directly mediating its effect.
The mitogenic effect of cAMP on cell proliferation in cystic
cells is dependent on protein kinase A (PKA)
Cyclic AMP can activate several downstream signalling path-
ways which can be PKA dependent or independent. In cystic
cells, the PKA inhibitor, H89, inhibited dbcAMP-stimulated
mitogenesis in a dose-dependent manner (Figure 4c).
This confirms previous reports that the cAMP phenotype is
PKA dependent.12
Knockdown of ras inhibits the combined effect of IGF-1 and
dbcAMP on cell proliferation
The efficacy of PI3-kinase and ERK inhibitors on IGF-1- and
cAMP-stimulated proliferation led us to investigate upstream
regulators of both pathways in cystic cells. The small
G-protein Ras is a key molecule that is known to activate
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Figure 1 | Mutational analysis of PKD1 and PKD2 and characterization of PC1 and PC2 expression in ADPKD cystic epithelial cell lines.
(a) The germline (and somatic ‘s’) mutations for each cystic line are displayed on the figure of PC1. (b) PC1 and PC2 expression was examined
by immunoblot using specific antibodies to both proteins: 7e12 (PC1) and p30 (PC2), respectively. ‘Full-length’ PC1 (4400 kDa) expression
ranged from being absent (OX161) to a clear reduction in the other four ADPKD cell lines compared with the normal cells (UCL93/3, CL11). Of interest,
smaller molecular weight bands were also detected with the N-terminal PC1 monoclonal antibody (7e12) in normal cells (B200 kDa) and in two
of the cystic lines (OX938 C7, SKI-001). It is possible that these may represent splice forms and mutant protein bands, respectively. Significantly,
PC2 expression was not affected by differences in the dosage of PC1 between lines. Actin was used to control for loading. (c) Genomic and cellular
DNA was screened for PKD1 and PKD2 mutations. The chromatograms indicate the germline and somatic PKD1 mutations present in OX161, and
the germline PKD1 mutation in SKI-001. The germline mutation in OX938 has been previously reported. No PKD2 mutations were detected.
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both PI3-kinase and ERK (via Raf and ERK kinase). All three
major isoforms of ras, namely N, K, H-Ras could be detected
in the SKI-001 cystic line by reverse transcription-polymerase
chain reaction (RT-PCR) (Figure 5a). By quantitative PCR
(Q-PCR), we confirmed that N-ras expression was the
highest of the three isoforms but there were no qualitative
or quantitative differences between cystic and normal cells
(data not shown).
Knockdown of ras mRNA was conducted using siRNA
previously validated on another SV40-transformed human
kidney cell line, HKC. In this line, the siRNA used achieved a
knockdown of 71% for H-Ras, 82% for K-Ras, and 76% for
N-Ras as assessed by Q-PCR. In our cystic line (SKI-001), we
were able to achieve a 490% transfection efficiency as
assessed by uptake of a fluorescent-labelled oligo using
lipofectamine (not shown). Significant and specific knock-
down of each isoform in SKI-001 was demonstrated by
semiquantitative RT-PCR (Figure 5a). Of relevance, the
combined IGF-1 and dbcAMP induced proliferative re-
sponses in cystic cells was abolished by each of the three ras
siRNA but not by an irrelevant control siRNA (Figure 5b).
Ras activation in cystic and normal cells
As both IGF-1 and cAMP responses appeared to be Ras
dependent, we next examined whether both agents
would activate Ras directly using a Ras activation assay. As
shown in Figure 6a, IGF-1 stimulation resulted in a twofold
increase in guanine 50-triphosphate (GTP)-Ras in cystic cells
but not in normal cells. dbcAMP alone had no discernible
effect on GTP-Ras levels in either cystic or control cells
(Figure 6a).
The Raf inhibitor BAY 43-9006 inhibits both IGF-1- and
cAMP-stimulated proliferation in cystic cells
Consistent with the effects of ras siRNA, the Raf inhibitor,
BAY 43-9006, inhibited both IGF-1- and dbcAMP-stimulated
cell proliferation in SKI-001 in a dose-dependent manner
(Figure 6b). Preincubation with BAY 43-9006 (0.5 mM)
blocked the increase in p44/42 ERK induced by IGF-1
but not of pAkt (Figure 6c). Although this compound can
inhibit other kinases, these results indicate that the inhibi-
tion of Raf-dependent ERK activation is the basis of this
response.
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Figure 2 | IGF-1 stimulates cell proliferation in the PKD1 cystic line, SKI-001, in the absence of LT antigen expression. (a) LT antigen
expression in SKI-001 cells was examined by monitoring cell growth at different temperatures over 96 h after plating; (b) immunoflurorescent
staining for LT after 72 h incubation at 331C (i) and 371C (ii). Each data point shown in (a) is the mean7s.e.m. of triplicate wells (n¼ 3).
Pan-cadherin expression in the cells was localized to intercellular junctions in cells incubated at 331C (iii) and 371C (iv). The effect of
recombinant human IGF-1 on cell proliferation was examined over a wide dose range (0.001–1000 ng/ml) in a normal (UCL93/3) and cystic
(SKI-001) cell line. Compared with the normal line, IGF-1 had a 3–4 times greater efficacy in stimulating cystic cell proliferation. (c) Results
are expressed as the % difference compared with control untreated cells7s.e.m. (*Po0.05) for three experiments performed in triplicate.
(d) These changes were mirrored in the changes in total cell counts between the two lines following IGF-1 treatment: a representative
experiment of three is shown in.
160 Kidney International (2007) 72, 157–165
o r i g i n a l a r t i c l e E Parker et al.: IGF-1 stimulates PKD1 cystic cell proliferation
DISCUSSION
One of the earliest changes evident in the PKD kidney is an
increase in tubular proliferative activity. We and others have
demonstrated that proliferating cells can be frequently
detected in tubular segments of normal calibre and often
are relatively sparse in larger cysts.6 These findings suggest
that the increase in proliferative activity is an early event and
may predispose these cells to the acquisition of a cystic
phenotype. In support of this, recent studies in rodent PKD
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Figure 3 | cAMP stimulates cell proliferation in PKD1 cystic but
not normal cell lines. (a) Several agents that increase cellular cAMP
concentrations such as dbcAMP (1 mM), forskolin (100 mM), and
3-isobutyl-l-methylxanthine (0.5 mM) stimulated an increase in
proliferation in the cystic line, SKI-001 but not the normal line, UCL
93/3. The graphs show the data from representative experiments
performed in triplicate. (b) The cAMP analogue dbcAMP (1 mM)
stimulated cell proliferation in three PKD1 cystic lines (OX938 C8,
OX161, and SKI-001) but not in three normal lines (CL11, RFH, UCL93).
Of note, the effect of IGF-1 (50 ng/ml) was additive to the cAMP
response in all three cystic lines. (c) The relative abundance of cell
surface IGF-1 receptors between the cystic and normal lines was
examined by surface biotinylation of the b subunit of the IGF-1
receptor. There was no difference in total (lysate) or surface (avidin IP)
levels of IGF-1 receptors between the two cell lines. The ER resident
protein calnexin served as a control for surface biotinylation and for
protein loading.
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Figure 4 | IGF-1- and dbcAMP-induced proliferation in cystic cells
can be blocked by ERK and PI3K inhibitors. (a) The combined
increase in cell proliferation mediated by IGF-1 and dbcAMP in the
three cystic cell lines (SKI-001, OX938 C8, and OX161) were inhibited
either by the ERK inhibitor (PD98059, 100 mM) or the PI3K inhibitor
(LY294002, 50mM). The effect was dose dependent (data not shown).
Data shown are representative of three experiments performed in
triplicate. (b) Pretreatment of the cells with either PD98059 (100mM)
or LY294002 (50 mM) before IGF-1 stimulation abolished activation of
ERK1/2 and Akt, respectively. dbcAMP stimulation had no detectable
effect on either ERK or Akt activation (data not shown). (c) The PKA
inhibitor, H-89, inhibited dbcAMP-stimulated cell proliferation in the
cystic line SKI-001 in a dose-dependent manner by. Data shown are
from three experiments performed in triplicate.
Kidney International (2007) 72, 157–165 161
E Parker et al.: IGF-1 stimulates PKD1 cystic cell proliferation o r i g i n a l a r t i c l e
models have demonstrated a direct correlation between
suppression of the cystic phenotype and a decrease in
proliferative activity in non-cystic tubules.7
An inverse relationship between PC1 dosage and cell
proliferation has been demonstrated by overexpressing the
heterologous gene, generating deficient cells from murine
knockout models, using antisense or a dominant negative
construct (isolated C-terminus).13–16 In summary, an increase
in PC1 expression suppresses and a decrease in PC1
expression or function increases the proliferative rate.
Nonetheless, the critical pathways that mediate the anti-
proliferative effect of PC1 (or PC2) have not been fully
elucidated. PC1 and PC2 have been shown to activate a
number of signalling intermediates such as small G-proteins,
cAMP and Ca2þ . These in turn can activate several pathways
including the JAK/STAT, Akt/PI3K, and ERK enzymes by
overexpression in heterologous systems. 13,17,18
As previous studies have utilized freshly isolated cystic
cells from ADPKD patients of uncertain genotype, we set out
to generate renal cystic lines from PKD1 patients with
defined germline mutations as model systems to exclude the
influence of genotype. Of interest, a reduced level of full-
length PC1 was detectable in four out of five PKD1 lines and
normal PC2 levels were present in all five lines. This suggests
that cystic transformation does not always require a ‘two hit’
(or transheterozygote) mechanism.19 In the one line with
absent PC1 expression (OX161), we found a single somatic
PKD1 mutation which is predicted to truncate the normal
PC1 protein. The finding of some PC1 expression in B80%
of the lines is consistent with our previous studies of PC1
expression by individual cysts in PKD1 kidneys with defined
germline truncating mutations.20 Nevertheless, apart from
the OX938 clones, the other lines were derived from a mixed
population of cystic cells so it is possible that a range of
different somatic PKD1 mutations which we did not detect
could be present.
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Figure 5 | Knock down of ras isoforms blocked the effect of IGF-1
and cAMP on cystic cell proliferation. (a) All three major ras
isoforms (N-, H-, Ki-) could be detected in normal and cystic cells
by RT-PCR (not shown). N-ras was the major isoform expressed by
Q-PCR. The specificity for each individual siRNA to knockdown
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three experiments performed in triplicate. Scrambled siRNA was used
as a negative control.
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Figure 6 | Ras and Raf activity in cystic cells stimulated with IGF-1
and cAMP. (a) Ras activation by IGF-1 and cAMP was investigated
using a commercial Ras activity assay which detects GTP-Ras. Total
Ras was detected using a pan-Ras antibody. One representative
experiment of three is shown. As a positive control, cell lysate was
treated with GTP-g-S before pull down with GST-Raf1-RBD (lane
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by twofold in cystic (SKI-001) but not in normal cells. DbcAMP (1 mM)
did not activate Ras in either cell line. (b) The Raf inhibitor, BAY
43-9006, inhibited IGF-1- and dbcAMP-stimulated proliferation in
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Two groups have previously described the additive effect
of EGF and cAMP on cell proliferation in ADPKD cystic
cells.21,22 However, the response to IGF-1 has not been
previously reported. Unlike IGF-1, the mitogenic response to
EGF has been reported to be the same between normal and
cystic cells.21,22 Overall, our findings suggest that PC1
deficiency may give rise to a lowered threshold for activation
of the ERK and Akt pathways by IGF-1 via the Ras/Raf
cascade. It has been reported that cyst epithelial cells isolated
from Pkd1 null mice kidney are hyperproliferative in the
presence of serum but not in its absence; in addition, they do
not grow in nude mice.14 This indicates that PC1 deficiency
gives rise to an increased sensitivity to growth factors but not
to autonomous cell growth.
We were able to reproduce the reported switch to a cAMP-
proliferative phenotype in three different PKD1 cystic cell
lines suggesting that this is a consistent finding relating to
PC1 deficiency. However, we observed a neutral rather than
an inhibitory effect of cAMP on basal or EGF-stimulated
proliferation of normal cell lines, similar to one previous
report.21,22 It has been reported that basal and stimulated
cAMP concentrations (as well as cAMP responsive currents)
in human ADPKD cystic cells are not significantly different to
normal cells.12,22 This implies that the cAMP mitogenic
response is not merely related to a change in cAMP synthesis
or degradation in cystic cells.
We found that blockade of Ras, Raf and ERK could abolish
the cAMP response in cystic cells and yet biochemical
evidence of acute cAMP activation of Ras or its downstream
effector ERK was not detected. These findings differ from
those described by another group who reported acute ERK
activation in response to cAMP analogues or cAMP
mobilizing agents although direct activation of Ras by cAMP
was not examined.12,22 One possibility is that this pathway is
permissive for the cAMP response in our cells rather than
directly mediating it. Alternatively, as cAMP may have both
acute and chronic effects on B-Raf, it may be that the longer
term effects of cAMP on the Ras–Raf pathway are more
important in our cells than the acute effects.23 Transgenic
expression of a H-Ras oncogenic mutant protein under the
control of a g-glutamyltranspeptidase (gGt) promoter is
associated with a renal cystic phenotype.24 However, we
found no difference in the efficacy of isoform-specific ras
siRNA to abrogate the mitogenic response to IGF-1 or
dbcAMP.
As Akt has been shown to inhibit B-Raf activity in normal
cells, it has been postulated that polycystin deficiency could
lead to a derepression of B-Raf by reducing PIP3-dependent
Akt activation. In support of this, incubation of M1 cells with
the PI3-kinase inhibitor (LY294002) or an Akt inhibitor was
associated with both a small increase in B-raf activity
(45 min) and a larger increase in total B-Raf protein
(5 h).23 Thus inhibition of Akt activity could lower the
threshold for cAMP stimulation of the Ras/Raf/ERK pathway
in M1 cells. Increased basal pAkt expression and PI3-kinase
activity have been reported in clonal MDCK cells over-
expressing PKD1.18 However, kidney pAkt levels were also
found to be elevated in a Pkd1 knockout mouse model
compared to controls.14 Thus the role of Akt in mediating the
cAMP mitogenic response requires further study.
Finally in preliminary studies, OX161 and SKI-001 were
found to predominantly form cysts in Type I collagen gels.
Further work will assess the efficacy of Ras–Raf inhibition in
inhibiting cyst growth in this system and other in vivo models
of ADPKD.25
MATERIALS AND METHODS
Generation of conditionally immortalized normal and cystic
cell lines
Conditional immortalized cystic (OX161/1, SKI-001, OX938) and
non-cystic (UCL93/3, RFH) epithelial cells were prepared from
tubular cells isolated from normal or PKD human kidneys
removed for clinical indications. Primary cultures were transduced
at an early passage (P1–4) with a replication-defective retroviral
vector containing the temperature-sensitive LT antigen and the
catalytic subunit of human telomerase.26 A shift to the permissive
temperature (33oC) allows activity of the LT antigen, which
destabilizes at higher temperatures (371C), as shown for the cystic
line SKI-001 (Figure 2). Cells were grown in Dulbecco’s modified
Eagle’s medium-Ham’s 12 (DMEM-F12) supplemented with 1%
L-glutamine, 5% NuSerum (Becton Dickinson, Oxford, UK) and
1% antibiotic/antimycotic solution (Invitrogen, Burlington, ON,
Canada).27 CL-11, a SV40LT-immortalized normal human proxi-
mal tubule line, was a gift from Dr L Racusen (John Hopkins,
Baltimore, MD, USA).
Mutation screening for PKD1 and PKD2 in genomic and cystic
DNA
All coding exons of the PKD1 and PKD2 genes were amplified from
genomic DNA by PCR using primers and protocols that we have
previously reported11,28 or newly developed unpublished primers.
For the duplicated portion of PKD1, a PKD1-specific long-range
PCR is generated as template for the nested PCR, as previously
described.11 Amplicons were analyzed for mutations by denaturing
high-pressure liquid chromatography (DHPLC) using the Wave
system 3500HT (Transgenomic Inc., Omaha, NE, USA) followed by
direct sequencing of abnormal chromatograms according to
previously described protocols.11 Mutations were validated by
means of analysis of a normal control population, by segregation
analysis in the family, by comparative genomics and bioinformatic
tools. They are numbered starting from the first ATG. Cellular DNA
from OX161/1 and SKI-001 was analysed for mutations.
Cell proliferation assay
Cystic and normal cells were seeded into 96-well plates at a seeding
density of 2 103 cells per well. Cells were grown in complete
medium for 24 h to reach 70% confluency after which cells were
cultured without serum for 48 h at 371C to induce quiescence. Cells
were then treated with IGF-1 (50 ng/ml) or dibutyryl cAMP
(dbcAMP, 1 mM) for a further 48 h at 371C. For inhibitor studies,
cells were pretreated with LY294002 (50mM), PD98059 (100 mM), or
BAY-43 9006 (0.5 mM) 2–4 h before stimulation. Cell prolifera-
tion was determined using the Promega Cell Titer 96 Aqueous One
assay (Promega, Southampton, UK). This assay showed a direct
correlation with the number of cells by cell counts as has been
described.22
Kidney International (2007) 72, 157–165 163
E Parker et al.: IGF-1 stimulates PKD1 cystic cell proliferation o r i g i n a l a r t i c l e
Ras isoform-specific siRNA transfection
Isoform-specific siRNA to human Ras was chemically synthesized by
Qiagen-Xeragon (Germantown, MD, USA) according to the
following sequences: N-RAS 50-AACTGGCCAAGAGTTACGGGA-30,
K-RAS 50-GGAGGGCTTTCTTTGTGTATT-30, HA-RAS 50-AAGCAG
GTGGTCATTGATGGG-30. A scrambled negative control siRNA
(Silencer) was purchased from Ambion (Austin, TX, USA).
Transfection of siRNA into cells was achieved using Lipofectamine
reagent (Invitrogen). To check transfection efficiency, fluorescent
oligos were utilized (BLOCK-iT, Invitrogen) and cells analysed after
24 h by fluorescent microscopy.
RNA analysis of specific ras isoforms
Cellular expression of ras mRNA was determined by RT-PCR using
isoform-specific primers: N-RAS forward 50-GAAAAGCGCACTGA
CAATCC-30, reverse 50-CACCACACATGGCAATCCC-30; Ki (4B)-
RAS forward 50-AGTGCCTTGACGATACAG-30, reverse 50-GCATC
ATCAACACCCTGTCTT-30; HA-RAS 50-CAAGAGTGCGCTGACC
ATCC30, reverse 50-CCGGATCTCACGCACCAAC-30. B-actin was
amplified as an internal standard using the sequences: forward
50-CCCACACTGTGCCCATC-30, reverse 50-TGATCCACATCTGC
TGGAAG-30. Total cellular RNA was extracted using TRIZOL reagent
(Invitrogen) and reverse-transcribed with a Retroscript Kit (Ambion,
CA, USA). DNA contamination of the RNA samples was removed by
using an Ambion DNA-free kit. Synthesized cDNA was utilized in a
RT-PCR reaction and analyzed by gel electrophoresis. Knockdown by
ras siRNA was assessed using semi-quantitative RT-PCR in the linear
range of the curve (21–23 cycles), utilizing b-actin as a control.
Quantitative PCR for specific ras isoforms
For Q-PCR, cDNA was reverse transcribed from total RNA using the
Omniscript reverse transcription kit from Qiagen and random
decamers (Promega). The 20 ml cDNA solution was made up to
100ml with RNAse-free water. Quantitative PCR was performed with
an Applied Biosystems PCR System in a volume of 25 ml, containing
TaqMan 2 Universal PCR Master Mix, cDNA, and optimized
primer/probe solutions for each of the ras isoforms. Ras isoform
cDNA levels were normalized to 18S ribosomal RNA.
Western blot analysis
Expression levels of PC1 and -2 were analyzed by immunoblotting
using specific antibodies raised to the N-terminus of PC1 (7e12) and
C-terminus of PC2 (p30). Detailed characterization of both
antibodies has been published.20,29
To assess the effect of IGF-1 and db-cAMP on ERK and Akt
activation, cells were made quiescent by a step-wise reduction of
serum initially to 1% for 48 h and then to serum-free medium for a
further 24 h. Cells were stimulated with IGF-1 or dbcAMP for
15 min with or without a 4 h pretreatment with kinase inhibitors.
Cells were solubilized in detergent lysis buffer (50 mM Tris, 0.14 M
NaCl, 0.4% Triton X-100, 1 mM Na3V04, 10 mM NaF) supplemented
with Complete protease inhibitors (Roche, Mannheim, Germany).
Supernatants were clarified by centrifugation and immunoblotting
performed as previously described.30 For quantitation, blots were
scanned using a Biorad model imaging densitometer and analyzed
by Multianalyst software.
Ras activity assay
Ras activation was measured using the EZ-Detect Ras activation kit
(Pierce, Rockford, IL, USA). The kit uses a GST-fusion protein
containing the Ras-binding domain (RBD) of Raf1 to specifically
pull-down active GTP-bound Ras. Cell lysates were incubated with
GST-Raf1-RBD and swellGel Immobilized Glutathione Disc. The
pulled-down active Ras was then detected by Western blotting using
a pan-Ras antibody. As a positive control, cell lysate was treated with
GTP-g-S prior to pull down with GST-Raf1-RBD.
Cell surface biotinylation for IGF-1 receptor
Cells were cultured to confluency in 10 cm dishes, washed three
times with phosphate-buffered saline and surface biotinylated with
sulfo-NHS-LC-Biotin (Pierce) before lysis as previously described.31
Equal amounts of cell lysate were incubated with 100ml streptavidin
beads overnight at 41C. After extensive washing, biotinylated
proteins were eluted in 2 sodium dodecyl sulfate loading buffer
and analyzed by sodium dodecyl sulfate-ployacrylamide gel electro-
phoresis and Western blotting using the antibodies described.
Statistical analyses
Mean and s.e.m. were calculated, and levels of significant difference
(Po0.05) were determined by the unpaired t-test.
Materials
Dibutyryl cAMP, forskolin, and 3-isobutyl-l-methylxanthine were
obtained from Sigma-Aldrich (Dorset, UK), LY294002, PD98059,
UO126 and H89 were purchased from Calbiochem (Nottingham,
UK). Antibodies to pAkt (Ser473), total Akt, p44/42 (ERK1/2), and
total p44/42 (ERK1/2) were purchased from Cell Signalling
Technology (Beverly, MA, USA). Antibodies to IGF-1 receptor
b chain, LT antigen and pan-cadherin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Cambridge
Bioscience (Cambs, UK). Recombinant human IGF-1 and the Raf
inhibitor, BAY-43 9006 were gifts of Chiron (Emeryville, CA, USA)
and Bayer (West Haven, CT, USA), respectively.
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